Current options in the treatment of mitochondrial diseases

Recent Patents on CNS Drug Discovery

Volumn 5, Issue 3, 2010, Pages 203-209

  Scarpelli, Mauro ^a   Cotelli, Maria Sofia ^b   Mancuso, Michelangelo ^c   Tomelleri, Giuliano ^a   Tonin, Paola ^a   Baronchelli, Carla ^b   Vielmi, Valentina ^b   Gregorelli, Valeria ^b   Todeschini, Alice ^b   Padovani, Alessandro ^b   Filosto, Massimiliano ^a,b  

^a UNIVERSITY OF VERONA   (Italy)

^b SPEDALI CIVILI   (Italy)

^c UNIVERSITY OF PISA   (Italy)

Author keywords

Coenzyme Q10; Drug therapy; Gene therapy; MELAS; Mitochondrial diseases; MNGIE

Indexed keywords

ADENINE NUCLEOTIDE TRANSLOCASE; ALPHA TOCOPHEROL; ASCORBIC ACID; BEZAFIBRATE; CARNITINE; CELL NUCLEUS DNA; CREATINE; CYTOCHROME C OXIDASE; DEFERIPRONE; DICHLOROACETIC ACID; FOLIC ACID; FRATAXIN; GLUTATHIONE; IDEBENONE; MANGANESE SUPEROXIDE DISMUTASE; MITOCHONDRIAL DNA; PARAQUAT; PLACEBO; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; PYRROLOQUINOLINEQUINONE; REACTIVE OXYGEN METABOLITE; RESTRICTION ENDONUCLEASE; RIBOFLAVIN; ROTENONE; TETRACYCLINE; THIAMINE; THYMIDINE PHOSPHORYLASE; TRANSFER RNA; UBIDECARENONE; WARFARIN;

AEROBIC EXERCISE; ALLOGENEIC STEM CELL TRANSPLANTATION; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; ATAXIA; CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; CLINICAL TRIAL; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOPAMINERGIC NERVE CELL; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ELECTRON TRANSPORT; ENERGY METABOLISM; EXERCISE TOLERANCE; FRIEDREICH ATAXIA; GASTROINTESTINAL DISEASE; GENE MUTATION; GENE REARRANGEMENT; GENE THERAPY; GENOTYPE PHENOTYPE CORRELATION; HETEROPLASMY; HUMAN; HUNTINGTON CHOREA; KEARNS SAYRE SYNDROME; LACTIC ACIDOSIS; LEBER HEREDITARY OPTIC NEUROPATHY; MELAS SYNDROME; MITOCHONDRIAL DNA DEPLETION; MITOCHONDRIAL DNA REPLICATION; MITOCHONDRIAL ENCEPHALOMYOPATHY; MITOCHONDRIAL GENETICS; MNGIE SYNDROME; MUSCLE REGENERATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARKINSON DISEASE; PHYSIOTHERAPY; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN EXPRESSION; RESPIRATORY CHAIN; VISUAL IMPAIRMENT;

ACIDOSIS, LACTIC; ANIMALS; ANTIOXIDANTS; DRUG DESIGN; EXERCISE THERAPY; GENE THERAPY; HUMANS; INTESTINAL PSEUDO-OBSTRUCTION; MITOCHONDRIAL DISEASES; MITOCHONDRIAL ENCEPHALOMYOPATHIES; THYMIDINE PHOSPHORYLASE;

EID: 78649360667     PISSN: 15748898     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488910793362412     Document Type: Article

References (82)

1. Filosto M, Mancuso M. Mitochondrial diseases: A nosological update. Acta Neurol Scand 2007; 115(4): 211-21.
2. DiMauro S, Schon EA. Mitochondrial respiratory-chain diseases. N Engl J Med 2003; 348(26): 2656-68.
3. Schafer AM, Mcfarland R, Blakely EL, He L, Whittaker RG, Taylor RW, et al. Prevalence of mitochondrial DNA disease in adults. Ann Neurol 2008; 63(1): 35-9
4. Mancuso M, Coppede F, Migliore L, Siciliano G, Murri L. Mitochondrial dysfunction, oxidative stress and neurodegeneration. J Alzheimers Dis 2006; 10 (1): 59-73.
5. Orsucci D, Filosto M, Siciliano G, Mancuso M. Electron transfer mediators and other metabolites and cofactors in the treatment of mitochondrial dysfunction. Nutr Rev 2009; 67(8): 427-38
6. Siciliano G, Volpi L, Piazza S, Ricci G, Mancuso M, Murri L. Functional diagnostics in mitochondrial diseases. Biosci Rep 2007; 27(1-3): 53-67
7. Santos RX, Correia SC, Wang X, Perry G, Smith MA, Moreira PI, et al. A synergistic dysfunction of mitochondrial fission/fusion dynamics and mitophagy in Alzheimer's disease. J Alzheimers Dis 2010; 20 (Suppl 2): S401-12
8. Cho DH, Nakamura T, Lipton SA. Mitochondrial dynamics in cell death and neurodegeneration. Cell Mol Life Sci 2010 June 25 [Epub ahead of print]
9. de Moura MB, dos Santos LS, Van Houten B. Mitochondrial dysfunction in neurodegenerative diseases and cancer. Environ Mol Mutagen 2010; 51: 391-405
10. Dodson MW, Guo M. Pink1, Parkin, DJ-1 and mitochondrial dysfunction in Parkinson's disease. Curr Opin Neurobiol 2007;17 (3): 331-7
11. Gu G, Reyes PE, Golden GT, Woltjer RL, Hulette C, Montine TJ, et al. Mitochondrial DNA deletions/rearrangements in parkinson disease and related neurodegenerative disorders. J Neuropathol Exp Neurol 2002; 61(7): 634-9
12. Onyango I, Khan S, Miller B, Swerdlow R, Trimmer P, Bennett P Jr. Mitochondrial genomic contribution to mitochondrial dysfunction in Alzheimer's disease. J Alzheimers Dis 2006; 9 (2): 183-93
13. Rahman S, Hanna MG. Diagnosis and therapy in neuromuscular disorders: Diagnosis and new treatments in mitochondrial diseases. J Neurol Neurosurg Psych 2009; 80(9): 943-53
14. Filosto M, Tomelleri G, Tonin P, Scarpelli M, Vattemi G, Rizzuto N, et al. Neuropathology of mitochondrial diseases. Biosci Rep 2007; 27(1-3): 23-30
15. Chinnery P, Majamaa K, Turnbull D, Thorburn D. Treatment for mitochondrial disorders. Cochrane Database Syst Rev 2006; 25(1): CD004426
16. Finsterer J. Treatment of mitochondrial disorders. Eur J Paediatr Neurol 2010; 14: 29-44
17. DiMauro S, Mancuso M. Mitochondrial diseases: Therapeutic approaches. Biosci Rep 2007; 27: 125-37
18. DiMauro S, Hirano M, Schon EA. Approaches to the treatment of mitochondrial diseases. Muscle Nerve 2006; 34(3): 265-83
19. Taivassalo T, Haller RG. Exercise and training in mitochondrial myopathies. Med Sci Sports Exerc 2005; 37(12): 2094-101
20. Gardner J, Craven L, Turnbull DM, Taykir RW. Experimental strategies towards treating mitochondrial DNA disorders. Biosci Rep 2007; 27: 139-50
21. Murphy JL, Blakely EL, Schaefer AM, He L, Wyrick P, Haller RG, et al. Resistance training in patients with single, large-scale deletions of mitochondrial DNA. Brain 2008; 131(11): 2832-40
22. Kaufmann P, Engelstad K, Wei Y, Jhung S, Sano MC, Shungu DC, et al. Dichloroacetate causes toxic neuropathy in MELAS: A randomized, controlled clinical trial. Neurology 2006; 66(3): 324-30
23. Salviati L, Sacconi S, Murer L, Zacchello G, Franceschini L, Laverda AM, et al. Infantile encephalomyopathy and nephropathy with CoQ10 deficiency: A CoQ10-responsive condition. Neurology 2005; 65(4): 606-8
24. DiMauro S, Gurgel-Giannetti J. The expanding phenotype of mitochondrial myopathy. Curr Opin Neurol 2005; 18(5): 538-42
25. Gempel K, Topaloglu H, Talim B, Schneiderat P, Schoser BG, Hans VH, et al. The myopathic form of coenzyme Q10 deficiency is caused by mutations in the electron-transferring-flavoprotein dehydrogenase (ETFDH) gene. Brain 2007; 130(PART 8): 2037-44
26. Gironi M, Lamperti C, Nemni R, Moggio M, Comi G, Guerini FR, et al. Late-onset cerebellar ataxia with hypogonadism and muscle coenzyme Q10 deficiency. Neurology 2004; 62(5): 818-20
27. Lamperti C, Naini A, Hirano M, De Vivo DC, Bertini E, Servidei S, et al. Cerebellar ataxia and coenzyme Q10 deficiency. Neurology 2003; 60(7): 1206-8
28. Musumeci O, Naini A, Slonim AE, Skavin N, Hadjigeorgiou GL, Krawiecki N, et al. Familial cerebellar ataxia with muscle coenzyme Q10 deficiency. Neurology 2001; 56(7): 849-55
29. Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, et al. Effects of coenzyme Q10 in early Parkinson disease: Evidence of slowing of the functional decline. Arch Neurol 2002; 59: 1541-50
30. Cleren C, Yang L, Lorenzo B, Calingasan NY, Schomer A, Sireci A, et al. Therapeutic effects of coenzyme Q10 (CoQ10) and reduced CoQ10 in the MPTP model of Parkinsonism. J Neurochem 2008; 104(6): 1613-21
31. Choi WS, Kruse SE, Palmiter RD, Xia Z. Mitochondrial complex I inhibition is not required for dopaminergic neuron death induced by rotenone, MPP+, or paraquat. Proc Natl Acad Sci USA 2008; 105: 15136-41
32. Ferrante KL, Shefner J, Zhang H, Betensky R, O'Brien M, Yu H, et al. Tolerance of high-dose (3,000mg/day) coenzyme Q10 in ALS. Neurology 2005; 65(11): 1834-36
33. Kaufmann P, Thompson JLP, Levy G, et al. Phase II trial of CoQ10 for ASL finds insufficient evidence to justify phase III. Ann Neurol 2009; 66: 235-44
34. Nakagawara, Akira., Liu, T.-L., KODA, T. Screening method for therapeutic agent for amyotrophic lateral sclerosis. EP2083085 (2009)
35. Albers DS, Beal MF. Mitochondrial dysfunction in progressive supranuclear palsy. Neurochem Int 2002; 40(6): 559-64
36. Stamelou M, Reuss A, Pilatus U, Magerkurth J, Niklowitz P, Eggert KM, et al. Short-term effects of coenzyme Q10 in progressive supranuclear palsy: A randomized, placebo-controlled trial. Mov Disord 2008; 23(7): 942-49
37. Spindler M, Beal MF, Henchcliffe C. Coenzyme Q10 effects in neurodegenerative disease. Neuropsychiatr Dis Treat 2009; 5: 597-610
38. Bonakdar RA, Guarneri E. Coenzyme Q10. Am Fam Physician 2005; 72: 1065-70
39. Yu-Wai-Man P, Griffiths PG, Hudson G, Chinnery PF. Inherited mitochondrial optic neuropathies. J Med Genet 2009; 46(3): 145-58
40. Tonon C, Lodi R. Idebenone in Friedreich's ataxia. Expert Opin Pharmacother 2008; 9(13): 2327-37
41. Goldberg AV, Molik S, Tsaousis AD. Localization and functionality of microsporidian iron-sulphur cluster assembly proteins. Nature 2008; 452 (7187): 624-8
42. Richardson DR, Huang ML, Whitnall M, Becker EM, Ponka P, Rahmanto YS. The ins and outs of mitochondrial iron-loading: The metabolic defect in Friedreich's ataxia. J Mol Med 2010; 88: 323-9
43. Di Prospero NA, Baker A, Jeffries N, Fischbeck KH. Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: A randomised, placebo-controlled trial. Lancet Neurol 2007; 6(10): 878-86
44. Tsou AY, Friedman LS, Wilson RB, Lynch DR. Pharmacotherapy for Friedreich ataxia.CNS Drugs 2009; 23: 213-23.
45. Qi X, Lewin AS, Hauswirth WW, Guy J. Suppression of complex I gene expression induces optic neuropathy. Ann Neurol 2003; 53(2): 198-205
46. Qi X, Lewin AS, Hauswirth WW, Guy J. Optic neuropathy induced by reductions in mitochondrial superoxide dismutase. Invest Ophthalmol Vis Sci 2003; 44(3): 1088-96
47. Manfredi G, Beal MF. Poison and antidote: A novel model to study pathogenesis and therapy of LHON. Ann Neurol 2004; 56(2): 171-2
48. Qi X, Lewin AS, Sun L, Hauswirth WW, Guy J. SOD2 gene transfer protects against optic neuropathy induced by deficiency of complex I. Ann Neurol 2004; 56(2): 182-91
49. Koga Y, Akita Y, Junko N, Yatsuga S, Povalko N, Fukiyama R, et al. Endothelial dysfunction in MELAS improved by L-arginine supplementation. Neurology 2006; 66(11): 1766-69
50. Garcia-Cazorla A, Quadros EV, Nascimento A, Garcia-Silva MT, Briones P, Montoya J, et al. Mitochondrial diseases associated with cerebral folate deficiency. Neurology 2008; 70(16): 1360-62
51. Pineda M, Ormazabal A, López-Gallardo E, Nascimento A, Solano A, Herrero MD, et al. Cerebral folate deficiency and leukoencephalopathy caused by a mitochondrial DNA deletion. Ann Neurol 2006; 59(2): 394-8
52. Gordon N. Cerebral folate deficiency. Dev Med Child Neurol 2009; 51(3): 180-2
53. Stephens FB, Constantin-Teodosiu D, Greenhaff PL. New insights concerning the role of carnitine in the regulation of fuel metabolism in skeletal muscle. J Physiol 2007; 581(Pt 2): 431-44
54. Tanaka M, Nishigaki Y, Fuku N, Ibi T, Sahashi K, Koga Y. Therapeutic potential of pyruvate therapy for mitochondrial diseases. Mitochondrion 2007; 7(6): 399-401
55. Komaki H, Nishigaki Y, Fuku N, Hosoya H, Murayama K, Ohtake A, et al. Pyruvate therapy for Leigh syndrome due to cytochrome c oxidase deficiency. Biochim Biophys Acta 2009; 17: 1-3
56. Jaksch M, Paret C, Stucka R, Horn N, Müller-Höcker J, Horvath R, et al. Cytochrome c oxidase deficiency due to mutations in SCO2, encoding a mitochondrial copper-binding protein, is rescued by copper in human myoblasts. Hum Mol Genet 2001; 10(26): 3025-35
57. Salviati L, Hernandez-Rosa E, Walker WF, Sacconi S, DiMauro S, Schon EA, et al. Copper supplementation restores cytochrome c oxidase activity in cultured cells from patients with SCO2 mutations. Biochem J 2002; 363(Pt 2): 321-27
58. Freisinger P, Horvath R, Macmillan C, Peters J, Jaksch M. Reversion of hypertrophic cardiomyopathy in a patient with deficiency of the mitochondrial copper binding protein Sco2: Is there a potential effect of copper? J Inherit Metab Dis 2004; 27(1): 67-79
59. Sgarbi G, Casalena GA, Baracca A, Lenaz G, DiMauro S, Solaini G. Human NARP mitochondrial mutation metabolism corrected with alpha-ketoglutarate/aspartate: A potential new therapy. Arch Neurol 2009; 66: 951-7
60. Omar A, Johnson LN. Tetracicline delays ocular motilità decline in chronic progressive external ophthalmoplegia. Neurology 2007; 68: 1159-60
61. Scarpulla R.C. Transcriptional paradigms in mammalian mitochondrial biogenesis and function. Physiol Rev 2008; 88: 611-38
62. Ekstrand MI, Falkenberg M, Rantanen A, Park CB, Gaspari M, Hultenby K, et al. Mitochondrial transcription factor A regulates mtDNA copy number in mammals. Hum Mol Genet 2004; 13: 935-44
63. Nishino I, Spinazzola A, Papadimitriou A, Hammans S, Steiner I, Hahn CD, et al. Mitochondrial neurogastrointestinal encephalomyopathy: An autosomal recessive disorder due to thymidine phosphorylase mutations. Ann Neurol 2000; 47(6): 792-800
64. Spinazzola A, Marti R, Nishino I, Andreu AL, Naini A, Tadesse S, et al. Altered thymidine metabolism due to defects of thymidine phosphorylase. J Biol Chem 2002; 277(6): 4128-33
65. Lara MC, Weiss B, Illa I, Madoz P, Massuet L, Andreu AL, et al. Infusion of platelets transiently reduces nucleoside overload in MNGIE. Neurology 2006; 67(8): 1461-3
66. Moran NF, Bain MD, Muquit MM. Carrier erythrocyte entrapped thymidine phosphorylase therapy for MNGIE. Neurology 2008; 71(9): 686-8
67. Yavuz H, Ozel A, Christensen M, Christensen E, Schwartz M, Elmaci M, et al. Treatment of mitochondrial neurogastrointestinal encephalomyopathy with dialysis. Arch Neurol 2007; 64(3): 435-8
68. Hirano M, Mart R, Casali C, Tadesse S, Uldrick T, Fine B, et al. Allogeneic stem cell transplantation corrects biochemical derangements in MNGIE. Neurology 2006; 67(8): 1458-60
69. Halter J, Schüpbach WM, Casali C, Elhasid R, Fay K, Hammans S, et al. Allogeneic hematopoietic SCT as treatment option for patients with mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): A consensus conference proposal for a standardized approach. Bone Marrow Transplant 2010; May 3 Epub ahead of print]
70. Flierl A, Chen Y, Coskun PE, Samulski RJ, Wallace DC. Adeno associated virus-mediated gene transfer of the heart/ muscle adenine nucleotide translocator (ANT) in mouse. Gene Ther 2005; 12(7): 570-8
71. Chinopoulos, C., Vajda, S., Csanády, L., Ádám-Vizi, V. An assay of adenine nucleotide translocase activity. WO2009013555 (2009)
72. Schon EA, DiMauro S, Hirano M, Gilkerson RW. Therapeutic prospects for mitochondrial disease. Trends Mol Med 2010; 16: 268-76
73. Minczuk M, Papworth MA, Miller JC, Murphy MP, Klug A. Development of a single-chain, quasi-dimeric zinc-finger nuclease for the selective degradation of mutated human mitochondrial DNA. Nucleic Acids Res 2008; 36(12): 3926-38
74. Manfredi G, Fu J, Ojaimi J, Sadlock JE, Kwong JQ, Guy J, et al. Rescue of a deficiency in ATP synthesis by transfer of MTATP6, a mitochondrial DNA-encoded gene, to the nucleus. Nat Genet 2002; 30(4): 394-9
75. Ellouze S, Augustin S, Bouaita A, Bonnet C, Simonutti M, Forster V, et al. Optimized allotopic expression of the human mitochondrial ND4 prevents blindness in a rat model of mitochondrial dysfunction. Am J Hum Genet 2008; 83(3): 373-87
76. Santra S, Gilkerson RW, Davidson M, Schon EA. Ketogenic treatment reduces deleted mitochondrial DNAs in cultured human cells. Ann Neurol 2004; 56(5): 662-9
77. Finsterer J, Segall L. Drugs interfering with mitochondrial disorders. Drug Chem Toxicol 2010; 33(2):138-51
78. Saneto RP, Lee IC, Koenig MK, Bao X, Weng SW, Naviaux RK, et al. POLG DNA testing as an emerging standard of care before instituting valproic acid therapy for pediatric seizure disorders. Seizure 2010; 19: 140-6
79. Mancuso M, Orsucci D, Volpi L, Calsolaro V, Siciliano G. Coenzyme Q10 in neuromuscular and neurodegenerative disorders. Curr Drug Targets 2010; 1: 111-21
80. Moreira PI, Zhu X, Wang X, Lee HG, Nunomura A, Petersen RB, et al. Mitochondria: A therapeutic target in neurodegeneration. Biochim Biophys Acta 2010; 1802(1): 212-20
81. Murphy MP, Smith RA. Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annu Rev Pharmacol Toxicol 2007; 47: 629-56
82. Yamada Y, Akita H, Kogure K, Kamiya H, Harashima H. Mitochondrial drug delivery and mitochondrial disease therapy: An approach to liposome-based delivery targeted to mitochondria. Mitochondrion 2007; 7: 63-71.